论文部分内容阅读
Background For patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB),adjuvant therapy with adefovir (ADV) has often been recommended.Unfortunately,a substantial proportion of the patients receiving the LAM-plus-ADV combination therapy show suboptimal virologic response.The efficacy of tenofovir disoproxil fumarate (TDF) in treating such patientsis not well known.